ClinicalTrials.gg
Not yet recruitingNCT07666035PERISEXUpdated Jun 26, 2026

Female Sexual Function After Surgery for Benign Perianal Diseases

An observational study in Chronic Anal Fissure, Hemorrhoidal Disease and Cryptoglandular Anal Fistula, sponsored by Gazi University. Not yet recruiting. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-06-26.

Sponsored by Gazi University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
120
Ages
18 Years to 70 Years
Sex
Female
01

Study summary

Benign perianal diseases such as chronic anal fissure, hemorrhoidal disease, and cryptoglandular anal fistula may negatively affect female sexual function through pain, bleeding, discharge, discomfort, and impairment in quality of life. Although improvement in male sexual function after surgery for benign anorectal disorders has been reported, data regarding female sexual function remain limited.

This prospective observational cohort study aims to evaluate changes in Female Sexual Function Index (FSFI) scores following surgical treatment of benign perianal diseases. Female patients undergoing surgery for chronic anal fissure, hemorrhoidal disease, or cryptoglandular anal fistula will be assessed preoperatively and at postoperative 3 and 6 months using the FSFI, Cleveland Clinic Incontinence Score (CCIS/Wexner), and Visual Analog Scale (VAS).

The primary objective is to determine whether female sexual function improves following surgical treatment. Secondary objectives include evaluating the relationship between symptom improvement, continence status, pain reduction, and changes in female sexual function.

Read the detailed description

Female sexual function is a multidimensional concept influenced by physical, psychological, and social factors. Benign perianal diseases are common surgical conditions that may adversely affect sexual function through chronic pain, bleeding, discharge, prolapse, discomfort, embarrassment, and reduced quality of life.

Previous studies have demonstrated impaired sexual function among patients with anorectal disorders. Furthermore, improvement in male sexual function following surgical treatment of benign anorectal diseases has been reported. However, prospective data regarding female sexual function after surgical treatment of benign perianal diseases remain scarce.

This single-center prospective observational cohort study will be conducted at Gazi University Faculty of Medicine. Sexually active women aged 18 to 70 years undergoing surgery for chronic anal fissure, hemorrhoidal disease, or cryptoglandular anal fistula will be enrolled.

Participants will complete the Female Sexual Function Index (FSFI), Cleveland Clinic Incontinence Score (CCIS/Wexner), and Visual Analog Scale (VAS) questionnaires before surgery and at postoperative 3 and 6 months.

The primary outcome will be the change in total FSFI score from baseline to postoperative 6 months. Secondary outcomes will include changes in FSFI at 3 months, changes in CCIS and VAS scores, and subgroup analyses according to disease type and symptom severity.

The investigators hypothesize that successful surgical treatment of benign perianal diseases will result in significant improvement in female sexual function and that this improvement will correlate with reductions in pain and disease-related symptoms.

02

Conditions studied

  • Chronic Anal Fissure
  • Hemorrhoidal Disease
  • Cryptoglandular Anal Fistula

Keywords

  • Cryptoglandular Anal Fistula
  • Chronic Anal Fissure
  • Hemorrhoidal Disease
  • FSFI
  • Sexual Functions
  • Perianal Pain
03

In context

Fissure in Ano

84 studies on the registry are indexed under Fissure in Ano; 16 are open to participants now.

This study's planned enrollment of 120 is above the median of 90 across 14 observational studies indexed under Fissure in Ano.

Browse Fissure in Ano studies →

Lead sponsor

Gazi University is the lead sponsor of 552 studies on the registry; 102 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Sexually active women undergoing surgical treatment for benign perianal diseases at Gazi University Faculty of Medicine.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients aged 18-70 years
  • Sexually active during the previous 4 weeks
  • Diagnosed with chronic anal fissure, hemorrhoidal disease, or cryptoglandular anal fistula
  • Scheduled for surgical treatment according to routine clinical indications
  • Able to understand and complete study questionnaires
  • Willing to provide written

Exclusion criteria

Exclusion Criteria:

  • Inflammatory bowel disease (Crohn's disease or ulcerative colitis)
  • Pregnancy
  • Postpartum period within the previous 12 months
  • Pelvic organ prolapse
  • Previous treatment for female sexual dysfunction
  • Current antidepressant medication use
  • Active psychiatric disorder
  • Gynecological
  • Previous pelvic radiotherapy
  • Inability or unwillingness to complete study questionnaires
  • Refusal to provide
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
120 participants (estimated)
Patient registry
No

Groups and cohorts

  • Women Undergoing Benign Perianal Surgery

    Sexually active female patients aged 18 to 70 years undergoing surgical treatment for benign perianal diseases, including chronic anal fissure, hemorrhoidal disease, and cryptoglandular anal fistula. Participants will be prospectively assessed using FSFI, CCIS/Wexner, and VAS scores at baseline and postoperative follow-up.

    Procedure: Surgical Treatment for Benign Perianal Diseases

Interventions

  • ProcedureSurgical Treatment for Benign Perianal Diseases

    Standard surgical treatment for chronic anal fissure, hemorrhoidal disease, or cryptoglandular anal fistula according to routine clinical indications. No experimental intervention will be administered.

06

What researchers measure

Primary outcomes

  1. Change in Total Female Sexual Function Index Score From Baseline to 6 Months

    Change in total Female Sexual Function Index (FSFI) score between the preoperative baseline assessment and postoperative 6-month follow-up. The FSFI total score ranges from 2 to 36, with higher scores indicating better female sexual function.

    Time frame: Baseline and postoperative 6 months

Secondary outcomes

  1. Change in Total Female Sexual Function Index Score From Baseline to 3 Months

    Change in total Female Sexual Function Index (FSFI) score between the preoperative baseline assessment and postoperative 3-month follow-up. The FSFI total score ranges from 2 to 36, with higher scores indicating better female sexual function.

    Time frame: Baseline and postoperative 3 months

  2. Change in Cleveland Clinic Incontinence Score From Baseline to 6 Months

    Change in Cleveland Clinic Incontinence Score/Wexner score between baseline and postoperative 6 months. The score ranges from 0 to 20, with higher scores indicating more severe fecal incontinence.

    Time frame: Baseline and postoperative 6 months

  3. Change in Visual Analog Scale Pain Score From Baseline to 6 Months

    Change in anal pain assessed using a 0-10 Visual Analog Scale between baseline and postoperative 6 months. Higher scores indicate more severe pain.

    Time frame: Baseline and postoperative 6 months

  4. Disease-specific Change in Total FSFI Score

    Comparison of change in total Female Sexual Function Index (FSFI) score among disease subgroups, including chronic anal fissure, hemorrhoidal disease, and cryptoglandular anal fistula. The FSFI total score ranges from 2 to 36, with higher scores indicating better female sexual function.

    Time frame: Baseline, postoperative 3 months, and postoperative 6 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Buyukkasap C, Bostanci H, Dikmen K, Gobut H, Yavuz A, Altiner S, Bolukbasi B, Atan A. Sexual Function After Surgical Treatment for Benign Anorectal Disorders. Am J Mens Health. 2024 May-Jun;18(3):15579883241252016. doi: 10.1177/15579883241252016. PubMed 38712744 ↗
  • Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, Ferguson D, D'Agostino R Jr. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000 Apr-Jun;26(2):191-208. doi: 10.1080/009262300278597. PubMed 10782451 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Feb 2028, 18 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2026
First posted
Jun 24, 2026
StartEst.
Aug 2026
Primary completionEst.
Feb 2028
CompletionEst.
Feb 2028
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07666035
Lead sponsor
Gazi University
Responsible party
Mesut YAVAS (Assistant of Professor of Surgery, Gazi University) — Principal investigator
First posted
Jun 24, 2026
Start date
Aug 2026 (estimated)
Primary completion
Feb 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
Jun 26, 2026

Study contacts

Mesut Yavaş, MD, Assistant of Professor
Contact
mesutyavas@gazi.edu.tr
+905019127287
Mesut Yavaş, MD, Assistant of Professor
principal investigator · Gazi University Faculty of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion